Conference Reports for NATAP

IAS 25th International AIDS Conference 22 to 26 July 2024 Back

Switching from a second-line ritonavir-boosted protease inhibitor (PI/r)-based regimen to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF): results of a randomized clinical trial       AIDS 2024 July 20-26 Munich